You are here

  • Home
  • Archive
  • Volume 73, Issue 9
  • Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Huizinga TWJ, Fleischmann RM, Jasson M, et al
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
Annals of the Rheumatic Diseases 2014;73:1626-1634.